LabPulse:
ChromaCode has begun an early-access commercial launch of a non-small cell lung cancer (NSCLC) assay that tests for variants in nine genes.
The test is designed to address diagnostic problems that prevent patients from undergoing timely cancer biomarker testing and receiving targeted therapies. A study of Medicare claims and laboratory data from 500,000 NSCLC patients found that half of the subjects were “lost to precision oncology because of factors associated with getting biomarker test results.” ChromaCode wants to tackle those factors.
